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Summary Chemokines such as regulated on activation, normal T-cell expressed and
secreted (RANTES), monocyte chemoattractant protein (MCP)-1, monocyte inflam-
matory protein (MIP)-1a have been reported to play an important role in the
pathogenesis of interstitial lung diseases. Among idiopathic interstitial pneumonia
(IIP), nonspecific interstitial pneumonia (NSIP) has elevated percentages of
lymphocytes in bronchoalveolar lavage (BAL) fluid compared with usual interstitial
pneumonia (UIP). These chemokines are candidate mediators for lymphocyte
attraction to the lung in NSIP. Therefore, we measured the BAL fluid levels of
RANTES, MCP-1 and MIP1-a in 15 patients with idiopathic NSIP, 20 with idiopathic UIP,
22 with sarcoidosis and 12 healthy volunteers to evaluate the contribution of these
chemokines using enzyme-linked immunosorbent assays. The levels of RANTES in BAL
fluid were significantly higher in patients with NSIP compared with healthy
volunteers (Po0:01), UIP and sarcoidosis (Po0:05). In MCP-1, the levels in BAL fluid
of NSIP and UIP patients were significantly elevated compared with healthy
volunteers and sarcoidosis patients (Po0:01). These results suggest that RANTES
and MCP-1 in BAL fluid may play an important role in inflammatory cell recruitment
to the lung in idiopathic NSIP as well as other interstitial lung diseases.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The classification of idiopathic interstitial pneumonia
(IIP) includes seven clinico-radiologic-pathologic en-
tities. Usual interstitial pneumonia (UIP) and non-
specific interstitial pneumonia (NSIP) are the two
largest subsets of IIP.1–3 NSIP is distinguished from UIP
by a temporal uniformity of interstitial inflammation
and/or fibrosis on histology.1–3 The distinction be-
tween NSIP and UIP is important for clinical
decision-making because the prognosis is generally
good and the response to corticosteroids and
immunosuppressants is also good in patients with
NSIP compared with UIP.1–3 It is well known that NSIP
has a relative lymphocytosis with a predominance of
CD8þ cells in BAL fluid when compared with UIP.4–6
An association between the lymphocytosis and the
levels of IL-6 in BAL fluid of patients with NSIP has
also been reported.5 These suggest that NSIP has a
pathogenesis different from UIP, but this still remains
unclear.
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It is well known that C–C chemokines such as
monocyte chemoattractant protein 1 (MCP-1),
macrophage inflammatory protein 1 alpha (MIP1-
a), and regulated upon activation, normal T-cell
expressed and secreted (RANTES) are closely
related to the expression of adhesion molecules
and the migration of inflammatory cells into the
lung. These chemokines have been reported to be
important factors in interstitial lung diseases.7–16
RANTES has been reported to be a chemotactic
factor of certain lymphocyte subsets, eosinophils,
monocytes and mast cells.14,17 MCP-1 is expressed
and released by a variety of cell types, including
leucocytes, smooth muscle cells, endothelial cells,
fibroblasts, epithelial cells, and alveolar macro-
phages, and is revealed to have selective chemo-
tactic activity of mononuclear phagocytes and
lymphocytes.7,9,18 MIP1-a is produced by appropri-
ately stimulated T cells, alveolar macrophages,
neutrophils, monocytes, airway epithelial cells,
and fibroblasts, and has been shown to have
chemotactic activity in T cells and monocytes.8,19
We have therefore hypothesized that these che-
mokins also mediate the recruitment of inflamma-
tory cells to the lung in NSIP.
In this study, we measured the BAL fluid levels of
RANTES, MCP-1 and MIP1-a in patients with NSIP,
UIP and sarcoidosis to evaluate the contribution of
these chemokines, and to determine whether there
is a distinct profile of these chemokines in the
diseases.
Materials and methods
Study population
The subjects of this study were patients and
healthy volunteers enrolled in the Hospitals of
Nagasaki University School of Medicine. The sub-
jects included 20 patients with idiopathic UIP (16
males and 4 females; mean age, 61 years; age
range 34–73), 15 with idiopathic NSIP (8 males and
7 females; mean age, 52 years; age range 28–72),
22 with pulmonary sarcoidosis (11 males and 11
females; mean age, 49 years; age range 23–75),
and 12 healthy volunteers (8 males and 4 females;
mean age, 26 years; age range 19–65). None of
these patients had received steroid therapy at the
time of clinical sample collection. Patients with
cancer in any organ and those suspected to have
malignancy were excluded from the study, and no
malignancy was detected in any patient during the
study. The diagnosis was pathologically confirmed
by surgical lung biopsy in all patients with UIP and
NSIP. Patients with UIP and NSIP associated with
collagen vascular diseases were excluded in this
study. The patients with sarcoidosis with pulmonary
lesions were also enrolled in the study. The
diagnosis was clinically established based on the
pathological findings of noncaseous epithelioid cell
granulomas in biopsy samples from lungs. The mean
%VC was significantly lower in NSIP (76.7718.3%,
Po0:01) and UIP (79.4722.9%, Po0:01) than in
sarcoidosis (97.9720.0) (Table 1), but there were
no significant differences in mean %VC between UIP
and NSIP. All healthy volunteers had normal chest
radiographs, were free of symptoms and were not
taking any medications. The study protocol was
approved by the Human Ethics Review Committees
of Nagasaki University School of Medicine, and a
signed consent form was obtained from each
subjects.
Bronchoalveolar lavage and cell preparation
Informed consent was obtained from all patients
and healthy volunteers, and BAL fluid samples were
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Table 1 Clinical characteristics of patients with nonspecific interstitial pneumonia (NSIP), usual interstitial
pneumonia (UIP) and sarcoidosis.
Normal subjects (n ¼ 12) NSIP (n ¼ 15) UIP (n ¼ 20) Sarcoidosis (n ¼ 22)
Age detection (yr) 26.6712.8 52.6713.4 61.079.8 5.0718.5
Sex (male/female) 8/4 8/7 16/4 11/11
Pulmonary function test
% VC(%) 76.7718.3 79.4722.9 97.9720.0a,b
FEV1.0% (%) 82.8714.9 84.077.4 79.2711.8
%DLCO (%) 63.5719.3 53.9725.7 58.4725.6
PaO2 (Torr) 76.3716.7 77.9715.5 83.3711.9
PaCO2 (Torr) 46.7713.8 45.279.2 41.073.7
Data are mean7SD.
aPo0:01; compared with NSIP (Fisher’s PLSD test).
bPo0:01; compared with UIP (Fisher’s PLSD test).
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obtained from all subjects. BAL was performed as
described previously20 using a flexible fiberoptic
bronchoscope (Olympus 1T-200, Olympus, Tokyo,
Japan) after local anaesthesia of the upper airway
with 4% lidocaine. Briefly, the bronchoscope was
wedged for lavage into one of the subsegmental
bronchi of the right middle lobe or, in patients with
peripheral opacities, into areas of lung parenchyma
otherwise normal on the chest radiograph. BAL was
performed four times using 50ml aliquot of sterile
physiologic saline solution at body temperature.
The BAL fluid was passed through two sheets of
gauze and then centrifuged at 500g for 10min at
41C. The remaining fluid was centrifuged at 500g
for 5min, and the supernatant was stored at 801C
for further quantification of noncellular compo-
nents. After washing twice with phosphate-buf-
fered saline solution (PBS), cells were suspended
with 10% heat-inactivated foetal calf serum and
counted using a haemocytometer. Differential cell
counts were determined from cell suspensions
displayed on slides using a cytocentrifuge (Cytospin
2; Shandon Instruments; Sewickley, PA). The cells
were dried, fixed on the slide, and then stained by
the May-Grunwald-Giemsa method. Two hundred
cells were identified under a photomicroscope.
Subsets of lymphocytes in BAL fluid were examined
by direct immunofluorescence staining using fluor-
escein isothiocyanate-labelled murine monoclonal
anti-CD3, CD4 and CD8 antibodies (Becton Dick-
inson; Mountain View, CA). The stained cells were
analysed on a flow cytometer (FACScan; Becton
Dickinson, FACS Division).
Measurement of RANTES, MIP-1a and MCP-1
Samples of BAL fluid were concentrated by Cen-
triprep-3 (Millipore Corporation; Billerica, MA),
which is used to concentrate low-molecular-weight
components. The cut-off value for molecular
weight is 3000 Da. In this procedure, the recovery
of each CC chemokines was 80%, and the magnifica-
tion of concentration was calculated by the ratio of
protein consistency in nonconcentrated BAL fluid to
concentrated BAL fluid, which was measured using
assay (DC protein Assay; Bio-Rad Laboratories;
Hercules, CA), and the original level of chemokines
was corrected by this ratio.21 The levels of RANTES,
MIP-1a and MCP-1 in BAL fluid were measured by
commercially available enzyme-linked immunosor-
bent assay kits (Quantikine; R&D systems, Minnea-
polis, MN) according to the protocols provided by
the manufacturer. The detection limits were 2.5,
5.0, 2.0 pg/ml for RANTES, MIP-1a; and MCP-1,
respectively. Since BAL producer has a dilutional
effect on the recovery of chemokines, measure-
ments are occasionally standardized to albumin. A
good correlation was observed between the non-
standardized and standardized values by albumin
concentrations in BAL fluid (data not shown), so the
chemokine levels reported in the text are those of
measured concentrations rather than those relative
to albumin concentrations.
Statistical analysis
All values were expressed as mean7standard
deviation (SD) or range. Differences between multi-
ple groups were compared by one-way analysis of
variance. The post hoc test used was Fisher’s PLSD
test. We also used Spearman’s rank correlation
analysis to examine the relationship. Statistical
analysis was performed using StatView-J 4.5 soft-
ware (Abacus Concepts; Berkeley, CA). Statistical
significance was defined by a P value of less than
0.05.
Results
Differential cell count of BAL fluid
Table 2 shows the characteristics of cells in BAL
fluid in all subjects. Cell recovery in patients with
UIP, NSIP and sarcoidosis is significantly higher than
in normal controls (Po0:01). In patients with UIP,
the percentages of macrophages were significantly
higher than those in patients with NSIP and
sarcoidosis (Po0:05). The percentages of lympho-
cytes in patients with NSIP and sarcoidosis were
significantly higher than in patients with UIP and
normal controls (P ¼ 0:01). The percentages of
neutrophils and eosinophils in UIP patients were
significantly higher than NSIP (Po0:05), UIP pa-
tients and normal subjects (Po0:01). The CD4/CD8
ratio in lymphocyte subsets in patients with
sarcoidosis was significantly the highest among all
subjects (Po0:01).
BAL fluid levels of RANTES, MIP-1a and MCP-1
As shown in Fig. 1, the levels of RANTES in BAL fluid
were significantly higher in patients with NSIP
(39.6714.6 pg/ml) compared with healthy volun-
teers (3.272.1pg/ml, Po0:01), UIP (12.37
18.0 pg/ml, Po0:05) or sarcoisosis (14.7734.4 pg/
ml, Po0:05). In MCP-1, the levels in BAL fluid
of NSIP (208.37241.7 pg/ml) and UIP patients
(153.47151.4 pg/ml) were significantly elevated
compared with healthy volunteers (12.379.0 pg/
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ml, Po0:01) and sarcoidosis patients (36.97
44.4 pg/ml, Po0:01). There were no significant
differences in the levels of MIP-1a in BAL fluid
among the groups.
Correlations between chemokine levels in
BAL fluid and clinical data
Since C–C chemokines are chemotactic factors for
lymphocytes, macrophages, and eosinophils, we
examined the association in the paired samples
between C–C chemokines and BAL fluid cells
obtained from the patients. In NSIP, significant
correlations were observed between the CD4/CD8
ratio or the percentage of CD8 cells and the levels
of RANTES in BAL fluid (Table 3). In sarcoidosis,
MCP-1 levels correlated with the percentages of
lymphocytes and the numbers of eosinophils
(r ¼ 0:472; Po0:05) in BAL fluid. MIP-1a levels also
correlated with the number of lymphocytes
(r ¼ 0:424; Po0:05) and the percentages and
numbers (r ¼ 0:546; Po0:05) of neutrophils, and
the number of eosinophils (r ¼ 0:571; Po0:01) in
BAL fluid of patient with sarcoidosis. RANTES levels
also correlated with the percentage of neutrophils
in BAL fluid of patients with sarcoidosis. In UIP,
correlations were also tested between chemokine
levels and the percentage and number of macro-
phages, lymphocytes, neutrophils, and eosinophils
in BAL fluid, but no association was found (data not
shown). However, there was a significant correla-
tion between RANTES levels in BAL fluid and %VC
(r ¼ 0:565; Po0:05), FEV1% (r ¼ 0:733; Po0:02) or
%DLCO (r ¼ 0:623; Po0:05) in UIP. In addition,
significant correlations were observed between
MCP-1 levels in BAL fluid and %VC (r ¼ 0:558;
Po0:05), FEV1% (r ¼ 0:743; Po0:02), or PaO2
(r ¼ 0:705; Po0:01) in patients with UIP. In
patients with sarcoidosis, there were significant
correlations between %VC and RANTES (r ¼ 0:707;
Po0:02), MCP-1 (r ¼ 0:577; Po0:05), or MIP-1a
(r ¼ 0:664; Po0:02). However, there was no sig-
nificant correlation between these chemokines and
pulmonary function tests in patients with NSIP.
Discussion
The major finding in this study was that patients
with NSIP and UIP had elevated concentrations of
RANTES and MCP-1 in BAL fluid. The BAL fluid levels
of RANTES in NSIP also increased significantly
compared with UIP and sarcoidosis. One of the
distinct clinical features of NSIP is a better
prognosis than that of UIP.1–3 It is therefore
important to clarify the differences of pathogenesis
between UIP and NSIP. The present finding of
lymphocytosis in BAL fluid of NSIP patients
compared with UIP is consistent with previous
reports.4–6 An accumulation of lymphocytes in the
airways of patients with NSIP suggested that
cytokines and chemokines contribute to chemotaxis
of inflammatory cell and activation in NSIP. In this
context, Park and colleagues demonstrated that
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Table 2 Total and differential cell counts in bronchoalveolar lavage fluid (BALF).
Normal subjects NSIP (n ¼ 15) UIP (n ¼ 20) Sarcoidosis (n ¼ 22)
Cell recovery 105 (ml) 1.370.8 4.172.0a 4.171.7a 3.872.2a
Cell differentials
Macrophages (%) 83.7714.4 58.2721.0a 75.4713.2a,b,c 55.5723.6a
Lymphocytes (%) 15.0713.9 34.1720.3a,d 13.879.6 41.9723.2a,d
Neutrophil (%) 0.971.0 3.273.3 5.676.3a,b,c 1.371.8
Eosinophil (%) 0.470.8 2.272.6 5.277.5a,b,c 1.070.1
Lymphocyte subsets
CD3 (%) 72.7725.0 84.8718.5 85.5714.3 90.177.3
CD4 (%) 34.6712.3 27.8715.9c,e 46.5720.3 57.2722.7a
CD8 (%) 45.0711.6 56.5721.8c,e 39.2717.8 29.9719.9a
CD4/CD8 0.970.5 0.770.7 1.671.3 3.072.1a,b,d
Data are mean7SD.
NSIP: nonspecific interstitial pneumonia, UIP: usual interstitial pneumonia.
aCompared with normal subjects (Po0:01).
bCompared with NSIP (Po0:05).
cCompared with sarcoidosis (Po0:01).
dCompared with UIP (Po0:01).
eCompared with UIP (Po0:05).
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the lymphocytosis in the lesion of patients with
NSIP is associated with the increased amount of IL-6
produced by the epithelial cells and the macro-
phages.5 The C–C chemokines such as RANTES,
MCP-1, and MIP-1a are also the major candidates
for inflammatory cell attraction to the lung in NSIP.
RANTES, which is a potent eosinophil and
lymphocyte attractant with particular preference
for CD45ROþ T cells, is thought to contribute to
the influx of inflammatory cells to the lung in
interstitial lung diseases.11,14,16 Petrek and collea-
gues demonstrated that RANTES is expressed at the
protein and mRNA level in the lower respiratory
tracts of patients with interstitial lung diseases,
that it is associated with the accumulation of
memory T-cells within the lung, and importantly
that the major sites of RANTES synthesis are
macrophages alone in sarcoidosis, but macrophages
and eosinophils in fibrosing alveolitis.14 Kodama and
colleagues also demonstrated that the expression
of RANTES mRNA by BAL fluid cells and the levels of
RANTES protein in BALF were significantly increased
in patients with IPF, sarcoidosis, and interstitial
pneumonia associated with collagen vascular
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Figure 1 BAL fluid concentrations of RANTES (A), MCP-1 (B), and MIP-1a (C) in patients with various lung diseases and
healthy volunteers. UIP, usual interstitial pneumonia; NSIP, nonspecific interstitial pneumonia.
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diseases (CVD-IP) compared with healthy volun-
teers.11 In our study, the levels of RANTES in BAL
fluid of NSIP were significantly higher than those in
UIP and sarcoidosis. This finding suggests that
RANTES may also mediate inflammatory cell influx
in NSIP. Petrek and colleagues reported that an
association was observed between RANTES mRNA,
both absolute and relative number of CD4þ
lymphocytes and also between this chemokine
and CD4/CD8 ratio in patients with sarcoidosis.16
It is therefore possible that RANTES is also involved
in the recruitment of CD4þ cells in NSIP. However,
the percentage and number of lymphocytes and
CD4 positive cells did not correlate with the
RANTES levels in BALF of patients with NSIP as well
as sarcoidosis in this study. It could be due to the
relatively small numbers of patients used in this
study. An additional clinical study will need to
rectify this problem.
In interstitial lung diseases, MCP-1 also appears
to be an important factor in the monocyte/
macrophage-mediated inflammatory process. Suga
et al. demonstrated that BAL fluid levels of MCP-1
in patients with IPF, IP-CVD and sarcoidosis were
significantly higher than in controls, and that the
level of MCP-1 in IPF was significantly higher than
that those in other interstitial lung diseases.13 In
lung tissues from IPF, metaplastic epithelial cells,
alveolar and interstitial macrophages, and vascular
endothelial cells are the major MCP-1 producing
cells.7,9 Thus, MCP-1 has been implicated predomi-
nantly in IPF rather than in sarcoidosis. Our finding
demonstrating the elevated levels of MCP-1 in IPF
patients compared with sarcoidosis patients and
controls is consistent with previous reports.13 In our
study, the levels of MCP-1 in BAL fluid of IPF
patients also correlated well with %VC, FEV1%, or
PaO2. These findings suggest that MCP-1 may play
an important role in the pathogenesis of IPF.
In sarcoidosis, no significant differences were
observed in the levels of MCP-1 compared with
controls. However, MCP-1 levels in BAL fluid of
patients with sarcoidosis correlated significantly
with the percentages of lymphocytes and the
numbers of eosinophils. These also correlated with
%VC. These findings suggest that MCP-1 may also
play an important role in the pathogenesis of
sarcoidosis while it may be smaller than in IPF. This
is supported by the findings reported by Petrek
et al. demonstrating that MCP-1 mRNA expression
was upregulated in sarcoidosis, particularly in
patients with more advanced disease.16 Hashimoto
and colleagues have also reported that plasma
MCP-1 levels in patients with active sarcoidosis
were significantly higher than in controls and the
changes in MCP-1 were closely related to the
clinical course of sarcoidosis.12 In NSIP, the levels
of MCP-1 in BAL fluid were significantly higher than
those in controls and sarcoidosis patients, but there
were no correlations between MCP-1 levels and BAL
cells or pulmonary function tests in this study.
Therefore, it remains unclear as to whether MCP-1
is a key factor in NSIP as well as UIP.
MIP-1a has been found to show augmented
expression in BAL fluid of both IPF and sarcoidosis
patients.8,16 MIP-1a is also expressed in the lungs
and promotes leucocyte accumulation and activa-
tion, leading to fibrosis in bleomycin-treated
mice.22 Treatment of bleomycin-challenged mice
with anti-MIP-1a antibody reduced accumulation of
pulmonary mononuclear phagocytes and fibrosis.22
MIP-1a preferentially mediates chemotaxis of CD8
rather than CD4 lymphocytes.19 From these find-
ings, we hypothesized that MIP-1a may contribute
to lymphocyte recruitment, especially CD8þ cells
into the lung in NSIP. However, there were no
significant differences in the levels of MIP-1a in BAL
fluid among the groups in this study. This is
consistent with a report by Petrek and colleagues
demonstrating that MIP-1a mRNA was present but
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Table 3 Correlation between chemokine and differential cell counts.
Spearman’s rank correlation
NSIP UIP Sarcoidosis
MCP-1 MIP1-a RANTES MCP-1 MIP1-a RANTES MCP-1 MIP1-a RANTES
Macrophages (%) 0.066 0.058 0.444 0.007 0.001 0.128 0.469* 0.454* 0.046
Lymphocytes (%) 0.108 0.186 0.363 0.167 0.223 0.251 0.456* 0.404 o0.01
Neutrophils (%) 0.259 0.268 0.301 0.021 0.363 0.045 0.054 0.480* 0.805*
Eosinophils (%) 0.194 0.404 0.064 0.181 0.011 0.140 0.191 0.306 0.114
CD4 (%) 0.045 0.216 0.301 0.166 0.080 0.084 0.302 0.267 0.109
CD8 (%) 0.451 0.028 0.639* 0.124 0.238 0.070 0.083 0.162 0.124
CD4/8 0.266 0.180 0.666* 0.180 0.039 0.008 0.162 0.149 0.135
*Po0:05:
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not upregulated in BAL fluid cells from sarcoisosis
patients.16 They and others23 also could not detect
MIP-1a protein in BAL fluid from sarcoisosis
patients. These data suggest that MIP-1a does not
contribute to inflammatory cell recruitment into
the lung in these diseases. However, MIP-1a levels
of BAL fluid of patients with sarcoidosis correlated
with the number of lymphocytes in BAL fluid and
%VC in this study. Further studies are therefore
required to define the role of MIP-1a in interstitial
lung diseases.
In conclusion, an elevation of RANTES and MCP-1
levels in BAL fluid was seen in NSIP while these
levels did not correlate with any clinical data
including BAL fluid cells and pulmonary function
tests. These results suggest that cytokine and
chemokine storm may occur in the lung of NSIP
patients, but other main mediators, e.g. IL-6,5 may
mainly play an important role in the pathogenesis
of NSIP.
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